The DOI matches its Crossref record.
A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.
Abstract
TPS2079 Background: GBM, the most common primary brain tumor in adults, has an aggressive clinical course and a median survival of 15–18 months in clinical trial populations. Approximately 40% of pts with GBM have tumors with an MGMT-methylated promoter, which is associated with sensitivity to TMZ. New treatment options for pts with GBM are desirable, particularly for those with MGMT-unmethylated GBM, as TMZ efficacy is historically marginal in this population. Nivolumab, a fully human IgG4 monoclonal antibody to the programmed death-1 receptor, has shown clinical activity and increased survival in pts with metastatic melanoma, non–small-cell lung cancer, and renal cell carcinoma. CheckMate-498 (NCT02617589) is a phase 3 study designed to compare overall survival (OS) of nivolumab or TMZ, each in combination with RT, in pts with newly diagnosed MGMT-unmethylated GBM. In a companion phase 2 trial (CheckMate-548; NCT02667587), eligible pts with MGMT-methylated tumors (N = 320) will be randomized to RT + TMZ + nivolumab vs RT + TMZ + placebo, with OS as the primary objective. Methods: Eligibility criteria include newly diagnosed, histologically confirmed, MGMT-unmethylated (centrally confirmed) GBM in pts aged ≥ 18 years with Karnofsky performance status ≥ 70. Pts with prior treatment for GBM and recurrent or secondary GBM are ineligible. Approximately 550 pts will be randomized to receive nivolumab + RT followed by nivolumab, or TMZ + RT followed by TMZ. Treatment will continue until progression or unacceptable toxicity. The primary objective is to compare OS with nivolumab + RT vs TMZ + RT; secondary objectives include progression-free survival and 2-year survival rate. Exploratory objectives include safety, biomarker analyses, and neurocognitive outcomes. Patients will be followed for safety and tolerability, tumor progression, and survival. At least 397 events, with an interim analysis after ≥ 298 events, will provide 90% power to detect a hazard ratio of < 0.72. Clinical trial information: NCT02617589.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, treatments that can induce HEV formation and/or increase antigen load, which include radiation, chemotherapy, and cancer vaccines, might enhance the therapeutic benefits of ICB101–104.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [103]
Citations
Cites
Still being checked.
Cited by
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Multidimensional communication in the microenvirons of glioblastoma
Broekman, M. L., Maas, S. L. N., Abels, E. R., Mempel, T. R., Krichevsky, A. M., & Breakefield, X. O. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0025-8 · Cited by 579
Signaling pathways and therapeutic approaches in glioblastoma multiforme (Review)
Khabibov, M., Гарифуллин, А., Boumber, Y., Khaddour, K., Fernandez, M., Khamitov, F., Халикова, Л. В., Kuznetsova, N. S., Kit, O. I., & Kharin, L. V. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5359 · Cited by 155
Glioblastoma: An Update in Pathology, Molecular Mechanisms and Biomarkers
Lan, Z., Li, X., & Zhang, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25053040 · Cited by 170
Duerinck, J., Schwarze, J. K., Awada, G., Tijtgat, J., Vaeyens, F., Bertels, C., Geens, W., Klein, S., Seynaeve, L., Cras, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002296 · Cited by 113
Metadata
- Authors
- Sampson, J. H., Omuro, A. M. P., Preusser, M., Lim, M., Butowski, N. A., Cloughesy, T. F., Strauss, L. C., Latek, R. R., Paliwal, P., Weller, M., & Reardon, D. A.
- Affiliations
- Duke Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Medical University of Vienna (AT)
- Johns Hopkins University (US)
- University of California, San Francisco (US)
- University of California, Los Angeles (US)
- Bristol-Myers Squibb (United States) (US)
- University Hospital Zurich (CH)
- Harvard University (US)
- ORCID
- Venue
- Journal of Clinical Oncology
- Published
- 2016-05-20
- Volume
- 34
- Issue
- 15_suppl
- Pages
- TPS2079-TPS2079
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2508076331
- Cited by
- 53
- References
- 0
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 5 · 2022: 18 · 2021: 7 · 2020: 4 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 1
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Oncology (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- glioblastoma, MGMT unmethylated, nivolumab, temozolomide, radiotherapy, immune checkpoint inhibitors, PD-1 inhibitors, overall survival, newly diagnosed glioblastoma, combination therapy, immunotherapy versus chemotherapy, MGMT promoter methylation, progression-free survival, neuropsychological outcomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. https://app.cochat.ai/papers/10.1200/jco.2016.34.15_suppl.tps2079
- The paper
- Sampson, J. H., Omuro, A. M. P., Preusser, M., Lim, M., Butowski, N. A., Cloughesy, T. F., Strauss, L. C., Latek, R. R., Paliwal, P., Weller, M., & Reardon, D. A. (2016). A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.34.15_suppl.tps2079
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.